Articles tagged with Molecular Targets
Scientists designed ring-shaped proteins targeting growth factor receptors to control human stem cell development. The resulting vascular networks formed tubes, healed, and absorbed nutrients, offering a new approach to repairing damaged hearts and kidneys.
Researchers at The Jackson Laboratory discovered a cascade of molecules that help coordinate the attack of cytotoxic T-cells on tumors. Elevated levels of IL-3 reenergize these cells, signaling them to resume detecting and destroying tumors, with rare basophils playing a key role in this process.
Researchers compiled over 100 investigators' data from more than two dozen countries, increasing human spaceflight data by 10-fold. The results revealed longer-lasting molecular and physiologic changes distinct between crew members, targeting new areas for aerospace medicine.
A new chelator, L804, reduces off-target toxicity in PSMA radiopharmaceutical therapy by improving the bond between radioactive metal ions and targeting antibodies. This makes the therapy safer and more effective for patients.
A team of researchers has created a water-soluble version of the bacterial enzyme histidine kinase, which could be used in high-throughput screens to rapidly test potential drugs that target this enzyme. The new protein retains its natural functions despite being converted from a hydrophobic protein.
Researchers have developed a route to modify peptides to target disease diagnostics and drug discovery, focusing on protein-protein interactions (PPIs). By modifying a small peptide sequence, the team showed it binds more quickly and strongly to specific PPI targets.
Researchers highlight strategies for improving agriculture with nanotechnology, including targeted delivery of pesticides and herbicides, and digital twin simulations. These approaches aim to reduce environmental pollution and increase crop resilience.
A team of researchers at University of California San Diego has identified a biochemical mechanism that can interrupt cellular communication chains, disrupting the signaling pathways related to many diseases. The discovery highlights the importance of growth factors and G protein-coupled receptors in cell signaling.
A new study reveals how accumulation of IMAT drives diseases such as muscle loss, type 2 diabetes, and cardiovascular disease. Regular exercise and healthy diet can prevent and reverse IMAT accumulation.
Researchers at Texas A&M University have discovered a new technique for tissue regeneration using mineral-based nanomaterials inspired by ancient medical practices. The approach aims to induce natural bone formation, reducing the need for invasive procedures and long-term medication, and promoting improved quality of life.
Researchers from Australia have shown that precision medicine can improve diagnosis accuracy and two-year progression-free survival in young cancer patients. By using whole genome sequencing, they were able to identify germline cancer predisposition variants in over 70% of children with high-risk cancers.
A new surgical platform using mass spectrometry identifies key gene mutations in brain cancer, including IDH mutations, during surgery. This allows for rapid diagnosis, prognosis, and tumor resection to improve patient outcomes.
A new study reveals TNIK's role in various diseases, including fibrosis, cancer, obesity, and Alzheimer's. The protein has been found to drive cancer cell proliferation and treatment resistance, while also regulating metabolic processes.
Researchers have identified genetic changes that can leave children born with little to no immune defense against infection. The study links mutations in the NUDCD3 gene to Severe Combined Immunodeficiency and Omenn syndrome, rare and life-threatening immunodeficiency disorders.
A national research effort found that eight weeks of endurance exercise training affected multiple bodily tissues and sparked widespread molecular responses in both male and female young adult rats. The study also revealed pronounced sex differences in some organs, such as the kidney.
Researchers found that miR-377 reduces MYC mRNA levels, leading to increased Bax and PTEN expression and decreased CDK4. This results in induced apoptosis, inhibited proliferation, and arrested cell cycle in prostate cancer cells.
A Cleveland Clinic-led team of scientists discovered that protein VISTA can directly turn off tumor-fighting T-cells during immunotherapy and resist treatment. The interaction between VISTA and a newly discovered inhibitory receptor LRIG1 suppresses T cell replication, survival, and function.
A recent study reveals that a cellular process called transfer Ribonucleic acid (tRNA) modification influences the malaria parasite’s ability to develop resistance. This breakthrough discovery could help researchers develop new drugs to combat resistance and better tools for studying RNA modifications.
A team of researchers led by Dr. Ahmed discovered that two FDA-approved antibiotics can induce heart regeneration in mammals, showing promise for treating heart failure. The study found that the antibiotics improved cardiac output and reduced fibrotic scar tissue, suggesting a potential new therapy.
Researchers identified 618 proteins linked to 19 types of cancer, including 107 in people diagnosed over 7 years prior. These proteins may be used to detect cancer earlier and prevent it altogether. Further research is needed to understand their role and develop reliable tests.
Insilico Medicine's lead compound demonstrates strong enzymatic activity, selectivity, and favorable ADME properties, as well as antitumor activity in various animal models. The company's generative AI-powered platform generated over 3,600 candidate molecules before identifying the promising lead compound.
Researchers discuss therapeutic opportunities for hypermutated urothelial carcinomas that are resistant to immunotherapy, including the potential of targeted therapies. High TMB is associated with defects in mismatch repair proteins and can lead to increased sensitivity to cancer treatments.
Researchers have identified a promising new vaccine adjuvant called C100, derived from chitin, which stimulates key sensing and signalling molecules to regulate anti-tumour immune responses. The discovery offers hope for developing effective adjuvants for in situ vaccines in cancer immunotherapy.
Researchers at UCLA Health Jonsson Comprehensive Cancer Center have found a combination immunotherapy treatment that enhances the immune response for people with malignant gliomas. Adding an immune-boosting agent, poly-ICLC, to a personalized dendritic cell vaccine improves the immune response and activity of T cells in patients.
The ECOG-ACRIN Cancer Research Group has launched the ComboMATCH-E5 trial, evaluating the combination of sotorasib and panitumumab in patients with KRAS G12C-mutated advanced solid tumors. The study aims to assess the efficacy and safety of the combination in this patient population.
Researchers at the University of Toronto have found a family of natural compounds that stall the unique metabolic process used by parasites to survive in the human gut. The discovery offers potential as new and more effective treatments for parasitic worm infections, which cause debilitating symptoms and developmental defects.
Researchers found that gut bacteria-generated linoleic acid metabolite KetoC markedly reduced inflammation and immune cell expansion. gKetoC also suppressed prolonged T-cell proliferation and dendritic cell activation. The study suggests a potential molecular axis governing the immunomodulatory effects of gKetoC.
A region in alpha-synuclein protein aggregates has been identified as a potential therapeutic target to prevent conversion into toxic amyloid fibrils, which accumulate in the brains of people suffering from Parkinson's disease. The discovery opens the door to developing new therapeutic strategies for inactivating these toxic forms.
The prevalence of lung cancer mutations varies significantly across different ethnic groups in Latin America, highlighting the need for region-specific medical interventions. Enhancing molecular diagnostic and research efforts is crucial for effective management of cancer in this population.
Researchers at U of T have identified two compounds, diindolylmethane and diindolylethane, produced by gut bacteria that can regulate the nuclear receptor CAR, potentially treating diseases like diabetes, fatty liver disease, and small intestine ulcerative colitis.
Researchers discovered a connection between mitochondrial calcium transport and autophagy, a process where cells break down and reuse components. The study found that NCLX protein plays a crucial role in regulating this link, which has implications for understanding energy metabolism and developing disease treatments.
Researchers at UCLA Health have developed a potential biomarker for stroke risk using a network of inflammatory molecules in the blood. The study, published in the journal Stroke, found that patients with higher concentrations of these molecules had an 84% chance of experiencing a stroke during their lifetime.
Researchers at the University of Toronto have found a way to better control the preclinical generation of key neurons depleted in Parkinson's disease. They developed an efficient method for stimulating stem cell differentiation to produce neural cells in the midbrain, which closely resemble dopaminergic neurons of natural origin.
A team of researchers has discovered the role a specific protein complex plays in certain forms of immune dysregulation. SHARPIN deficiency is linked to autoinflammation and immunodeficiency, but unexpectedly does not manifest dermatological issues. Treatment with anti-TNF therapies resolves symptoms.
New therapies aim to strengthen the body's immune responses and restore antimicrobial functions to combat TB. Researchers have identified small molecule compounds that reduce Mtb growth inside immune cells by up to 50-75%, suggesting a potential complement to standard therapy.
Researchers at University of Kansas discover a new compound that inhibits SARS-CoV-2 replication in cell models by targeting the 'Mac-1' protein. This finding offers hope for developing new treatments and preventing future pandemics.
Researchers at Weill Cornell Medicine have discovered a way to boost protective effects of sphingolipids in blood vessels, slowing the development and progression of coronary artery disease. The study suggests revising current views on ceramides' role in the disease, instead finding that their levels remain stable in endothelial cells.
Researchers at NJIT are developing a hydrogel therapy that prevents viruses like SARS-CoV-2 from attaching to and entering cells. The peptides in the gel form a 'molecular mask' that muffles the virus's action, providing a potential first line of defense against biological threats.
Researchers propose a new strategy to further enhance the performance of gas sensors using single-atom catalysts. The review discusses the application, structure, and principles of semiconductor-based gas sensors, as well as the mechanisms through which single-atom catalysts improve gas sensitivity.
Researchers at H. Lee Moffitt Cancer Center & Research Institute discovered a new therapeutic target for non-small cell lung cancer by targeting the Jagged2 protein. Disrupting this signaling pathway activates anti-tumor immunity via Notch-induced functional reprogramming of tumor-associated macrophages.
Researchers at UCSF have identified laryngeal and tracheal neuroendocrine cells that sense water and acid in the upper airway, triggering a cough reflex. The discovery could lead to interventions to prevent pneumonia and treat certain types of chronic cough.
Researchers led by Gavin Sacks found that molecular sulfur dioxide levels are key to preventing the rotten egg smell in canned wine. The team recommends maintaining low levels of SO2 and using epoxy liners to minimize hydrogen sulfide production. This could improve the aroma and lifespan of canned wines.
Researchers investigate how early-stage Alzheimer's disease affects memory formation by examining synaptic connections and amyloid beta. The study aims to understand the role of NMDA receptors in synaptic plasticity and how they might be hijacked by amyloid beta, leading to memory dysfunction.
Researchers at UC Riverside demonstrate a new vaccine strategy targeting a common viral genome part, eliminating the need for annual booster shots. The vaccine uses small RNA molecules to boost the immune system, making it safe for babies and those with weakened immunity.
Mayo Clinic researchers have invented a new class of artificial intelligence (AI) algorithms called hypothesis-driven AI, which can help discover the complex causes of diseases like cancer and improve treatment strategies. This emerging class of AI offers an innovative way to use massive datasets to guide individualized medicine.
The National Science Foundation has awarded Amplified Sciences a $275,000 Phase 1 Small Business Innovation Research grant to develop novel ultrasensitive optical reporter platform technology for early detection of pancreatic cancer. The company aims to improve diagnosis and treatment outcomes with its multiplexing capabilities.
Researchers have identified TL1A, an alarmin molecule, as a key trigger for allergic reactions in respiratory diseases like asthma and rhinitis. The molecule cooperates with interleukin-33 to stimulate immune cells, leading to inflammation and treatment targets are being explored.
Researchers highlight the role of post-transcriptional RNA modifications in AML pathogenesis, identifying m6A and m7G regulators as potential therapeutic targets. Targeted therapies, including selective inhibitors and Traditional Chinese Medicine compounds, show promise in promoting cell differentiation and reversing AML phenotypes.
A study found that proteogenomic signatures in prostate cancer tissue from patients with African and European ancestries were associated with a higher risk of metastasis and/or recurrence. The study identified mutation signatures and recurrent copy number alterations that correlated with disease progression.
Researchers have identified three new subgroups of neuroblastoma based on genetic traits, expected outcomes, and distinguishing features. These subgroups offer clues as to which treatments may be most effective, potentially improving prognosis and quality of life for children with cancer.
Researchers at Insilico Medicine developed QFASG, a quantum-assisted algorithm generating novel small-molecule structures from fragments. The tool successfully designed inhibitors for cancer-related proteins, showcasing its potential in accelerating drug discovery and development.
MD Anderson researchers presented studies on combination therapies for AML and lung cancer, tumor microbiomes in immunity, and improved HPV screening. Genetic markers predict extended survival with KRAS inhibitors and may identify patients who benefit from novel combinations.
Researchers developed a novel theranostic platform that combines PET imaging and therapeutic radionuclides to detect and treat ovarian cancer. The system uses the huAR9.6 antibody to target the MUC16 protein, showing promise for improved patient survival rates.
Researchers developed a prediction tool to classify proteins based on their potential to bind RNA G-quadruplexes, showing high protein disorder and hydrophilicity. This discovery provides insights into gene expression and phase-separation into membrane-less organelles.
Dr. Rhonda Voskuhl's groundbreaking research has shed light on the mechanisms underlying sex differences in MS, highlighting a gene on female sex chromosomes that promotes inflammation and brain-protective effects of estrogen. Her work may lead to new treatment approaches for MS.
Researchers at Mayo Clinic have developed an immunotherapy strategy that combines chimeric antigen receptors with mesenchymal stromal cells, known as CAR-MSCs. This approach shows potential in targeting inflammatory disease sites more precisely and improving immunosuppression and healing outcomes for autoimmune diseases.
Researchers have identified distinct molecular signatures associated with sepsis, enabling more accurate diagnosis and prognosis. The study's findings suggest a potential new tool to target specific therapies at patients most likely to develop severe symptoms.
Researchers at Weill Cornell Medicine have identified mutations in the ARID1A gene that drive follicular lymphoma transformation into a more aggressive form. These mutations make patients highly susceptible to experimental BAF-inhibitor drugs, offering new hope for early intervention therapies.
Researchers develop AI-powered method to rapidly predict multiple protein configurations, understanding protein dynamics and functions. This breakthrough has the potential to revolutionize drug discovery by uncovering more targets for new treatments.
Researchers have identified PDE4B as a potential target for treating Alzheimer's disease, where reducing its activity shows promise in improving memory and glucose metabolism. The study suggests that this approach may also protect against other forms of dementia, such as Huntington's disease.